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ABSTRACT
Objective Although gastric per-oral endoscopic
myotomy (G-POEM) is considered a promising technique
for the management of refractory gastroparesis, high-
quality evidence is limited. We prospectively investigated
the efficacy and safety of G-POEM in unselected patients
with refractory gastroparesis.
Design In five tertiary centres, patients with
symptomatic gastroparesis refractory to standard medical
therapy and confirmed by impaired gastric emptying
were included. The primary endpoint was clinical success,
defined as at least one score decrease in Gastroparesis
Cardinal Symptom Index (GCSI) with ≥25% decrease
in two subscales, at 12 months. GCSI Score and
subscales, adverse events (AEs) and 36-Item Short Form
questionnaire of quality of life were evaluated at baseline
and 1, 3, 6 and 12 months after G-POEM. Gastric
emptying study was performed before and 3 months
after the procedure.
Results Of 80 enrolled patients, 75 patients (94%)
completed 12-month follow-up. Clinical success at 12
months was 56% (95% CI, 44.8 to 66.7). GCSI Score
(including subscales) improved moderately after G-POEM
(p<0.05). In a regression model, a baseline GCSI Score
>2.6 (OR=3.23, p=0.04) and baseline gastric retention
>20% at 4 hours (OR=3.65, p=0.03) were independent
predictors of clinical success at 12 months, as was early
response to G-POEM at 1 month after therapy (OR 8.75,
p<0.001). Mild procedure-related AEs occurred in 5 (6%)
patients.
Conclusion G-POEM is a safe procedure, but showed
only modest overall effectiveness in the treatment of
refractory gastroparesis. Further studies are required to
identify the best candidates for G-POEM; unselective use
of this procedure should be discouraged.
Trial registration number ClinicalTrials.gov Registry
NCT02732821.

INTRODUCTION

Gastroparesis is a morbid disorder, characterised by
delayed gastric emptying in the absence of mechanical obstruction.1 Over the past two decades, gastroparesis has been a growing concern in terms of
prevalence, economic cost and its negative effect

Significance of this study
What is already known on this subject?

►► Gastroparesis is a morbid disorder that remains

difficult to treat with limited therapeutic
options.
►► Gastric per-oral endoscopic myotomy (G-POEM)
is a minimally invasive procedure that has
shown promising results for the management
of refractory gastroparesis.
What are the new findings?

►► G-POEM was only modestly effective in patient

with gastroparesis with a clinical success rate
of 56% at 12 months.
►► Serial assessment of gastroparesis symptoms
showed that the response to G-POEM was
durable throughout the course of the study.
►► Baseline gastric retention >20% at 4 hours and
symptom severity were independent predictors
of clinical success 12 months after G-POEM.
How might it impact on clinical practice in the
foreseeable future?
►► The accurate mid-term clinical success and
durability of outcome helps clinicians to better
decide about performing G-POEM.
►► Our findings of mid-term clinical success and
durability of G-POEM may help physicians
to choose the best therapeutic strategy for
patients with refractory gastroparesis.
►► G-POEM may be considered in patients with
more severe baseline symptoms and pre G-
POEM gastric retention.

on quality of life.2–4 Despite its high burden, gastroparesis remains a difficult-to-treat condition with
limited treatment options. One large multicentre
prospective study showed that only 28% of patients
had clinical success at 48 weeks after receiving treatment according to the standard of care.5 Impairment of fundic accommodation, antral contractility,
pyloric relaxation and/or duodenal feedback may
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METHODS
Study design

We designed an international multicentre, prospective study
to evaluate the safety and efficacy of G-POEM and its effect
on gastroparesis-related symptoms, quality of life and gastric
emptying.

G-POEM procedure and post procedure management

Procedures were performed by interventional endoscopists
in the endoscopy unit under general anaesthesia. Details of
the G-POEM procedure have been described previously.22 In
summary, intravenous antibiotics were administered before the
procedure, and carbon dioxide insufflation was used throughout
the procedure. G-POEM starts with creating a submucosal bleb
4–5 cm proximal to the pylorus along the greater curvature by
injecting saline and 0.25% indigo carmine or methylene blue
solution. A longitudinal 1.5 cm mucosal incision is made and
the endoscope is introduced into the submucosal space. A tunnel
is created and carefully extended by dissecting the submucosal
fibres until the pyloric ring is identified. As the submucosal
dissection is extended towards the pylorus, attention is paid
to ensure the mucosal layer is not breached and the scope is
correctly advancing towards the pylorus. A single myotomy is
performed once the pyloric ring is identified from the most distal
aspect of the pylorus with 2–3 cm extension proximally towards
the antrum and entails full-thickness pyloromyotomy involving
circular and oblique muscle bundles. Finally, the mucosal incision is closed using endoscopic clips (online supplemental video
1). On day 1 post procedure, an upper GI series was performed
for all patients to rule out any leakage. In case of normal upper
GI series, patients were started on a full liquid diet with transition to soft diet if tolerated. Subsequently, if patients tolerated the oral diet without vomiting, they were discharged with
instructions to stay on soft diet for 10–14 days. The diet was
subsequently advanced to a low residue diet as tolerated.

Assessments and outcome measures

Patients

Patients with refractory gastroparesis referred for possible
G-POEM at five participating centres were eligible for the study.
Following a detailed description of the intended procedure,
patients were invited to participate in the study if they were
deemed eligible. Eligible participants were patients with refractory gastroparesis, aged 18 years or older. Refractory gastroparesis was defined as gastroparesis symptoms (nausea, vomiting,
early satiety, belching, bloating and/or upper abdominal pain) in
the absence of mechanical obstruction which are refractory to
standard medical therapy (including diet, lifestyle modification
and prokinetics) and confirmed by impaired gastric emptying.
Baseline symptom severity was not an inclusion criterion.

Table 1

Exclusion criteria were previous surgery of the oesophagus or
stomach which has resulted in a resection of the antrum and
pylorus, known active gastro-
oesophageal malignancy, prior
surgical or laparoscopic pyloromyotomy, active opioid abuse,
upper gastrointestinal (GI) bleeding conditions, use of anticoagulation therapy which could not be discontinued and pregnancy
or expecting to become pregnant. Eligible patients provided
written, informed consent before enrolment in the study.

At baseline and at 1, 3, 6 and 12 months, the Gastroparesis
Cardinal Symptom Index (GCSI) Score, use of prokinetics,
36-Item Short Form (SF-36) quality of life questionnaire and
AEs were recorded. Gastric emptying scintigraphy (GES) was
performed at baseline and 3 months post G-POEM. Table 1
provides an overview of the plan of the study assessments. At
baseline and each follow-up, the local site investigator contacted
the participants and asked the items of GCSI and SF-36 questionnaire and recorded prokinetic use and any AEs.
GCSI, a patient-reported tool for assessment of severity of
gastroparesis symptoms, includes three subscales of postprandial fullness/early satiety (four items), nausea/vomiting (three
items) and bloating (two items). GCSI total score and each

Study plan and schedule
Baseline

During the procedure

1 month

3 months

6 months

12 months

GCSI Score

✓

 

✓

✓

✓

✓

Use of prokinetic medication

✓

 

✓

✓

✓

✓

SF-36 questionnaire of quality of life

✓

 

✓

✓

✓

✓

Adverse events

✓

✓

✓

✓

✓

✓

Gastric emptying study

✓

 

 

✓

 

 

GCSI, Gastroparesis Cardinal Symptom Index; SF-36, 36-Item Short Form.
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contribute to delayed gastric emptying and clinical symptoms.6 7
Treatment of gastroparesis remains challenging due to contribution of various pathophysiologic mechanisms to the disease. Diet
modification and prokinetic medications are first-line therapies
of gastroparesis. However, prokinetics are not tolerated well due
to their significant side effects and have suboptimal efficacy.8
Pylorospasm, detected by manometry9 and endoluminal
impedance planimetry (EndoFLIP; Medtronic, Minneapolis,
Minnesota),10–12 has been shown to correlate with gastroparesis
symptoms. Based on these findings, pyloric-directed interventional procedures such as botulinum toxin injection, transpyloric
stent placement and pneumatic dilation of the pylorus have been
developed.13–16 Unfortunately, long-term efficacy of these interventions has not been confirmed in robust prospective studies.
Gastric per-oral endoscopic myotomy (G-POEM) was introduced by Khashab et al17 in 2013 as a minimally invasive
pyloric-
directed procedure for the management of refractory
gastroparesis. This was followed by several studies, mostly
retrospective with short follow-
up periods, which showed
encouraging results.18 19 Two meta-
analyses reported pooled
symptomatic improvement rates of 83.9% and 82% and adverse
events (AEs) rate of 6.8% and 6.1%, respectively.20 21 These
results have contributed to our knowledge about efficacy and
safety of G-
POEM; however, the literature remains scarce,
and prospective multicentre trials with mid-term to long-term
follow-up are lacking.
In this international multicentre, prospective study, we
aimed to assess clinical success of G-POEM for the management of refractory gastroparesis 12 months after the procedure.
Secondary aims were to evaluate safety, change in quality of life
and change in gastric retention over the course of the study.

Endoscopy

Gastroparesis aetiology
Patients were classified into one of the three categories of postsurgical, diabetic and idiopathic gastroparesis. Patients with
gastroparesis symptoms and delayed gastric emptying following
a surgery with high probability of vagal nerve injury—eg,
fundoplication, oesophagectomy, pancreatectomy, Roux-
en-
Y
anastomosis and heart and lung transplant27—were classified
in the postsurgical gastroparesis group. According to a general
consensus, patients with diabetic gastropathy and delayed gastric
emptying were classified in the diabetic gastroparesis group.28
Patients with gastroparesis of unknown cause were classified into
the idiopathic gastroparesis group. Patients with concomitant
systemic, neurologic and psychiatric disorders as well as those
on medications with a possible relationship (but without a clear
causality association) to gastroparesis symptoms were reported
in the idiopathic gastroparesis group.

Statistical analysis
We aimed at evaluating the outcomes of G-POEM in patients
with refractory gastroparesis in a single arm prospective observational study. Simulation studies suggest that for observational
studies with dichotomous outcomes, at least 60 participants
would be needed to provide sufficiently tight CIs for the prospective evaluation of outcomes, which then can be used as the basis
Vosoughi K, et al. Gut 2021;0:1–9. doi:10.1136/gutjnl-2020-322756

for future randomised controlled trials (RCTs).29 Accordingly,
we planned a sample size of 80 patients.
Descriptive statistics for patient demographics, baseline characteristics and procedural data are presented as mean±SD for
normally distributed continuous variables, median and 25th–
75th percentiles for ordinal variables or continuous variables
with non-normal distribution and count and percentage for categorical variables.
The primary endpoint was reported as the percentage of
patients with clinical success at 12 months. Multiple paired
t-tests with Bonferroni correction were used to compare total
and subscales of GCSI scores at follow-ups with the baseline
values. Friedman test was performed for analysis the change
of each domain of the SF-36 questionnaire from baseline and
month follow-
up period, and Wilcoxon signed
across the 12-
ranks test was used to compare 12-month values with the baseline. The rate of normalised GES was reported at 3 months and
the 4-hour gastric retention at 3 months was compared with
baseline using a paired t-test. Logistic regression model was used
to determine baseline predictive parameters. Baseline variables
with p value<0.02 were tested in a multivariable logistic regression model to identify independent baseline predictors of clinical
success. Statistical analyses were performed using SPSS software
(SPSS V.16.0). Two-sided p value<0.05 was considered as statistically significant.
Missing values of GCSI subscales were imputed using multiple
imputation (MI) by fully conditional specification (FCS).30 FCS
MI uses functions conditionally on the information of a set of
given variables to impute the missing values on a variable-by-
variable basis. FCS was used since this method (unlike joint
modelling, the major iterative alternative for doing MI) is flexible in using different regression models for each variable (eg,
linear regression for continuous variables and logistic regression
for categorical variables).31 Moreover, simulation studies have
shown that FCS MI generally provides unbiased estimates with
appropriate coverage.32 33
The following variables were given to the model to impute
missing values of GCSI subscales: available GCSI scores
(including baseline), age, sex, body mass index (BMI), aetiology
of gastroparesis, duration of gastroparesis and previous treatments. (132/1200 (11%) missing values for GCSI subscales at
interim and 12-month follow-ups.) A total of 50 imputations
were carried out with 100 iterations each. Missing values of
average GCSI were calculated using the imputed GCSI subscale
values. The missing values of quality of life, medication use and
post G-POEM GES were not imputed.

Patient and public involvement

Patients and/or the public were not involved in the design,
conduct, reporting or dissemination plans of this research.

RESULTS

Between November 2015 and November 2018, 80 patients at
five centres fulfilled the study criteria. The number of patients
recruited from each centre is displayed in online supplemental
table 1. All 80 patients underwent successful G-POEM (100%
technical success). Five patients did not complete the 12-month
follow-up: four patients were lost to follow-up and one patient
was not able to answer follow-up questions due to several hospital
admissions for non-gastrointestinal medical issues. This resulted
in 75 patients (94% of the sample population) who completed
the 12-month follow-up with respect to the primary endpoint
(figure 1). For the 80 participants, the mean age was 49.3±14.9
3
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of the three subscales are 5-point Likert scales with 0=none,
1=mild, 2=moderate, 3=severe and 4=very severe.23 Clinical
success was defined as at least one score decrease in the total
GCSI scoring system with more than a 25% decrease in at least
two of the subscales as previously defined by Mekaroonkamol
et al.24 The primary endpoint was clinical success at 12 months
after G-POEM.
Initially, when the study started at 2015, the primary endpoint
was defined as GCSI Score below 2 at 12 months after G-POEM.
However, as the knowledge of the field evolved, in January
2019, the primary endpoint was revised as defined above. The
rate of patients with mean GCSI <2 has also been reported for
comparison with the results of the modified primary endpoint.
Secondary endpoints of the study were clinical success at 1,
3 and 6 months, the change in average GCSI, GCSI subscales,
prokinetic medication use and SF-36 quality of life score at 1, 3,
6 and 12 months and change in gastric retention at 3 months.
SF-36 questionnaire was used to assess eight domains of quality
of life including physical function, bodily pain, role-physical,
general health, vitality, social function, role-
emotional and
mental health.12 GES was performed before and 3 months after
the procedure. The percentage of gastric retention was measured
by scintigraphy after ingestion of low-fat, egg-white meal labelled
with radioactive technetium.13 Abnormal GES was defined as
gastric retention greater than 10% at 4 hours after ingestion.25
GES at 3 months was compared with preprocedure GES, and
a reduction of at least 50% in gastric retention percentage at 4
hours was considered as GES improvement.
Safety of G-
POEM was evaluated by the frequency and
severity of the procedure-related AEs. Site principal investigators
(PIs) recorded and rated severity, attribution and timing of AEs
based on the American Society for Gastrointestinal Endoscopy
lexicon’s classification system.26 During G-
POEM, procedure
details including duration of the procedure, length of incision,
tunnel and myotomy and number of clips used alongside technical success (completion of the procedure using the assigned
approach) and intraprocedure AEs were recorded by the site PIs.

Endoscopy
G-POEM procedure details
Median (25th–75th percentiles)

Length of myotomy (cm)

2 (1.5–2)

Length of tunnel (cm)

5 (4–6)

Length of incision (cm)

2 (2–2)

Number of clips
Procedure time (min)
Length of hospital stay (days)

5 (4–6)
43 (34–56.5)
1 (1–1)

G-POEM, gastric per-oral endoscopic myotomy.

postsurgical (n=28, 35%) and diabetes (n=19, 23.8%). Further
details related to each aetiology group are presented in online
supplemental table 3.
The G-POEM procedure was completed in 80 patients (100%
technical success). Median (25th–75th percentiles) procedure
time was 43 (34–56.5) min. All procedures were completed with
the greater curvature approach (table 3).

Efficacy

Figure 1 Enrolment flow diagram. G-POEM, gastric per-oral
endoscopic myotomy.
(mean±SD) years and 57 (71.3%) were females. All patients had
received prokinetic medications before enrolment. A total of 56
patients (70%) had previously been treated with intrapyloric
botulinum toxin injection and/or transpyloric stent placement.
Mean GCSI total score at baseline was 2.8±1.1 and mean gastric
retention at 4 hours was 39%±22% (table 2). Online supplemental table 2 displays demographics and clinical characteristics in patients with complete 12-month follow-up versus those
with missing 12-month follow-up. The most common aetiology
of gastroparesis was idiopathic (n=33, 41.3%), followed by
Table 2

Demographics and patient characteristics*
G-POEM
(n=80)

Age—years

49.3±14.9

Sex—no. (%)
Male

23 (28.7%)

Female

57 (71.3%)

BMI—kg/m2

26.14±5.99

Previous treatment—no. (%)
Prokinetic only

24 (30%)

Prokinetic and botulinum toxin injection

28 (35%)

Prokinetic and transpyloric stenting

16 (20%)

Prokinetic, botulinum toxin injection and transpyloric stenting

12 (15%)

Median disease duration (25th–75th percentiles)—months

36 (18–61)

Average GCSI Score at baseline

2.8±1.1

GCSI nausea/vomiting score at baseline

2.5±1.4

GCSI fullness/early satiety score at baseline

3.4±1.2

GCSI bloating subscale score at baseline

2.7±1.5

Gastric retention percent at 4 hours before the G-POEM

39±22

Median time difference between baseline GES and G-POEM (25th– 16 (2.5–33.5)
75th percentiles)—months
*± values are means±SD.
BMI, body mass index; GCSI, Gastroparesis Cardinal Symptom Index; GES, gastric
emptying scintigraphy; G-POEM, gastric per-oral endoscopic myotomy.
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Clinical success was achieved in 42 of 75 patients (56% (95% CI,
44.8 to 66.7)) at 12 months (the study’s primary endpoint). Clinical
success at the interim follow-ups were 57.5% (95% CI, 46.1 to 68.2)
at 1 month, 61.5% (95% CI, 49.4 to 72.4) at 3 months and 60.3%
(95% CI, 48 to 71.5) at 6 months after G-POEM.
Analyses of the total 80 participants using the imputed data
obtained similar clinical success rates (57.3% (95% CI, 46.3 to 67.5)
at 1 month and 56.3% (95% CI, 45.3 to 66.6) at 12 months).
At 12 months, GCSI Score <2 was observed in 51 of 75
patients (68%, 95% CI, 56.8 to 77.5) in the population with
completed 12-month follow-up and in 53 of 80 (66.6%, 95%
CI, 55.8 to 76) in the complete 80 patients, using the imputed
data (table 4).
Clinical success rate at 12 months was generally consistent
across gastroparesis subtypes: 59.3% (95% CI, 40.7 to 75.5)
in the postsurgical group, 52.9% (95% CI, 31 to 73.8) in the
diabetic group and 54.8% (95% CI, 37.7 to 70.8) in the idiopathic gastroparesis group (p=0.913). Clinical success rate and
proportion of patients with GCSI Score <2 at 12 months are
reported by baseline treatment groups and participating centres
in online supplemental table 4.
Average GCSI decreased from 2.8±1.1 (mean±SD) at baseline
to 1.6±1.1 at 1 month (1.2±1.3 reduction compared with baseline, p<0.001) and to 1.5±1.2 at 12 months (1.3±1.3 reduction
compared with baseline, p<0.001) (figure 2A).
Nausea/vomiting score decreased from 2.5±1.4 at baseline to
1.2±1.2 at 1 month (1.2±1.3 reduction, p<0.001); however,
it increased slightly over the course of the study and reached
1.4±1.4 at 12 months (1.02±1.6 reduction compared with
baseline, p<0.001) (figure 2B). Postprandial fullness decreased
by 1.3±1.7, from 3.4±1.2 at baseline to 2.1±1.5 at 1 month.
The improvement continued and the score reached 1.8±1.4
at 12 months (1.5±1.5 reduction from baseline, p<0.001)
(figure 2C). Likewise, bloating score decreased from 2.7±1.5 at
baseline to 1.5±1.5 at 1 month (1.1±1.6 reduction from baseline, p<0.001) and further decreased to 1.3±1.5 at 12 months
(1.3±1.7 reduction from baseline, p<0.001) (figure 2D).

Quality of life

A comparison of eight aspects of quality of life scores measured
at baseline and 12 months, together with analysis of change in
scores over the time course of the study, are shown in table 5.
Vosoughi K, et al. Gut 2021;0:1–9. doi:10.1136/gutjnl-2020-322756
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Table 3

Procedural data

Endoscopy
Clinical success rate and rate of patients with GCSI total score below two across the follow-up time points
1 month

3 months

6 months

12 months

Number

Percent (95% CI)

Number

Percent (95% CI)

Number

Percent (95% CI)

Number

Percent (95% CI)

Clinical success* (available date)

42/73

57.5 (46.1 to 68.2)

40/65

61.5 (49.4 to 72.4)

38/63

60.3 (48 to 71.5)

42/75

56 (44.8 to 66.7)

Clinical success* (imputed data†)

45.8/80

57.3 (46.3 to 67.5)

46.8/80

58.5 (47.6 to 68.7)

49.7/80

62.1 (51.2 to 72)

45/80

56.3 (45.3 to 66.6)

Patients with GCSI <2‡ (available date)

49/73

67.1 (55.7 to 76.8)

40/65

61.5 (49.4 to 72.4)

38/63

60.3 (48 to 71.5)

51/75

68 (56.8 to 77.5)

Patients with GCSI <2‡ (imputed data†)

52.7/80

65.8 (55 to 75.3)

47.4/80

59.3 (48.3 to 69.4)

47/80

58.8 (47.8 to 68.9)

53.3/80

66.6 (55.8 to 76)

*Clinical success was defined as one score decrease in the five-point GCSI Score plus at least 25% decrease in two of the three GCSI subscales. The collected data showed that
25% decrease equals to 0.62 for nausea/vomiting, 0.84 for fullness/early satiety and 0.66 for bloating subscales.
†No. of patients with imputed observations: 7 (8.8%) at 1 month, 15 (18.8%) at 3 months, 17 (21.3%) at 6 months and 5 (6.3%) at 12 months.
‡The study’s initial primary endpoint.
GCSI, Gastroparesis Cardinal Symptom Index.

There was a significant improvement in the majority of the
quality of life aspects both at 12 months and over time. All
components improved at 12 months except for physical functioning, role limitation due to physical health and bodily pain,
which showed no significant change.

Gastric emptying study
Three months after G-POEM, GES was performed in 53 of the
80 patients (66%). Gastric retention at 4 hours was compared
with the baseline values. Mean (±SE) gastric retention at 4 hours
decreased significantly from 39±22% at baseline to 21±27% at
3 months, which resulted in GES improvement in 64.2% (34 of
53 cases). At 3 months, gastric retention normalised in 47.2%
(25 of 53 cases) of the patients.
At 3 months, clinical success rate was 75.8% (25 of 33 cases) in
patients with GES improvement compared with 38.9% (7 of 18
cases) in those who did not show GES improvement (p=0.015).
Similarly, decrease of gastric retention at 4 hours and change
in mean GCSI Score at 3 months were found to be moderately
positively correlated (r=0.29, p=0.046).

Safety

AEs were recorded and rated in all participants (n=80). No
unanticipated AEs were reported. Five AEs (6.2%) were
reported, all of them were rated as mild and were reported to be
procedure related. AEs included symptomatic capnoperitoneum
in three patients, all were successfully managed with needle
decompression, mucosotomy in one patient, treated successfully
by stent replacement and one thermal mucosal injury, treated
with clipping.

Predictors of 12-month clinical success

Predictors of 12-
month clinical success were evaluated using
univariable logistic regression model. Baseline GCSI Score higher
than 2.6, fullness/early satiety GCSI subscale, gastric retention of
more than 20% at 4 hours before G-POEM and clinical success
at 1 month were positively associated with 12-month clinical
success (p<0.05) (table 6). Clinical success rate was constantly
higher in patients who achieved 1-
month clinical success
compared with those with clinical failure at 1 month. At 12
months, clinical success rate in patients who achieved 1-month
clinical success was 79%, compared with 30% in those with clinical failure at 1 month (p<0.001) (figure 3).
Multivariable analysis was performed for evaluation of
preprocedure predicting factors. Our model showed that higher
baseline GCSI Score higher than 2.6 (OR=3.23, p=0.04)
and baseline gastric retention of more than 20% at 4 hours
(OR=3.65, p=0.029) were independent predictors of clinical
success at 12 months (table 7).

DISCUSSION

Figure 2 Change in GCSI Score after G-POEM over 12-month follow-
up. Data presented as mean±95% CI over follow-ups in (A) average
GCSI, (B) nausea/vomiting, (C) postprandial fullness/early satiety and (D)
bloating scores. Analysis with paired t-test with Bonferroni correction
was performed. *Number of imputed observations at each time point:
7 (9%) at 1 month, 15 (19%) at 3 months, 17 (21%) at 6 months and
5 (6%) at 12 months. **Indicates significant difference compared with
baseline values (adjusted p value<0.0125). GCSI, Gastroparesis Cardinal
Symptom Index; G-POEM, gastric per-oral endoscopic myotomy.
Vosoughi K, et al. Gut 2021;0:1–9. doi:10.1136/gutjnl-2020-322756

This international, multicentre, prospective study presents
mid-
term outcomes of G-
POEM in patients with refractory
gastroparesis. G-POEM resulted in a modest improvement of
average GCSI and subscale scores which were sustained at 12
months post procedure. Almost half of the patients responded to
G-POEM which is considerably lower than the rates reported by
previous studies.20 21 Our findings do not support regular use of
G-POEM in the general patient population without identifying
the optimal G-POEM candidates. Prospective data collection as
part of formal institutional review board (IRB)-approved protocols is paramount to help researchers identify patients who have
a high likelihood of response to G-POEM. Our data also showed
that G-POEM resulted in a larger decrease of GCSI Score in
patients with more severe symptoms and higher gastric retention
at baseline. These criteria are important for future studies on
G-POEM. Larger studies are needed to determine further selection criteria.
5

Gut: first published as 10.1136/gutjnl-2020-322756 on 19 March 2021. Downloaded from http://gut.bmj.com/ on April 22, 2021 at Henry Ford Hospital. Protected by copyright.

Table 4

P value

Age

1.02

(0.99 to 1.05)

0.293

Female versus male

1.41

(0.52 to 3.83)

0.501

BMI

0.96

(0.88 to 1.04)

0.272

 Diabetes*

0.93

(0.28 to 3.03)

0.9

 Postsurgical*

1.2

(0.42 to 3.4)

0.735

Duration of gastroparesis

1

(0.99 to 1.02)

0.551

Upper abdominal pain before G-
POEM

1.27

(0.95 to 1.69)

0.11

Baseline GCSI Score higher than 2.6† 3.84

(1.43 to 10.30)

0.008

Baseline average GCSI Score

1.94

(1.19 to 3.17)

0.008

Baseline nausea/vomiting score

1.38

(0.97 to 1.96)

0.077

Baseline Fullness/early satiety score

1.68

(1.12 to 2.54)

0.013

Baseline bloating score

1.41

(1.02 to 1.95)

0.036

3.24

(1.07 to 9.78)

0.037

8.75

(2.9 to 26.38)

<0.001

Prescribed opioids

0.4

(0.14 to 1.19)

0.099

Cannabinoid

0.59

(0.15 to 2.4)

0.46

Prokinetics at 12 months

0.5

(0.1 to 2.42)

0.389

Prokinetics at any of the follow-up
time points

0.83

(0.29 to 2.37)

0.732

0.021

<0.001

0.038

<0.001

0.034

<0.001

0.008

<0.001

P value†

0.216

0.004
−5.3 (−10.4 to −0.3)

−19.8 (−27.2 to −12.3)

<0.001

0.004
−6.3 (−11.7 to −0.9)

−18.6 (−25.4 to −11.9)

0.002
−14 (−20.3 to −7.7)

<0.001

0.071

0.085
−14.5 (−25.3 to −3.7)

−14.2 (−26.7 to −1.6)

Bold indicates a statistically significant difference with a p-value less than 0.05.
*P values were determined from tests for trend using repeated-measures analysis whether the domains of quality of life improve over time (Friedman’s test).
†P values were determined by comparing 12 months and baseline values (Wilcoxon signed ranks test).
G-POEM, gastric per-oral endoscopic myotomy; SF-36, 36-Item Short Form.

68.75 (45–90)

40 (25–65)
45 (27.5–65)

57.5 (43.125–87.5)
57.5 (33.125–85.625)

45 (30–65)
45 (30–61.25)

57.5 (32.5–80)

37.5 (25–55)

45 (22.5–67.5)
Bodily pain

General health

72 (56–88)

75 (37.5–100)
75 (50–87.5)

72 (60–80)
68 (56–83)

50 (25–62.5)
Social functioning

68 (57–83)

56.25 (50–87.5)

64 (52–80)
Mental health

62.5 (38.125–87.5)

50 (30–75)
50 (30–70)
50 (30–65)
40 (20–55)
Vitality

55 (27.5–70)

100 (33.3–100)

62.5 (0–100)
50 (0–100)

100 (33.3–100)

50 (0–100)

100 (33.3–100)

25 (0–100)

100 (0–100)

0 (0–75)

66.7 (0–100)

Role limitation due to physical health

Role limitation due to emotional problems

Mean (95% CI)

−14.8 (−21.6 to −8)
87.5 (56.25–100)
85 (60–97.5)
82.5 (45–95)
77.5 (50–98.75)
70 (35–91.25)

Median (25th–75th
percentiles)
Median (25th–75th
percentiles)
Median (25th–75th
percentiles)

Median (25th–75th
percentiles)

6 months (n=61/80,
76%)

GES results

Physical functioning

P value*

 Idiopathic

Median (25th–75th
percentiles)

Change over the
course of the study
Difference between
baseline and 12 months

95% CI

Aetiology

3 months (n=64/80,
80%)

12 months (n=72/80,
90%)

OR
Baseline characteristics

Pre G-POEM (n=80/80, 1 month (n=72/80,
100%)
90%)

Change of eight domains of quality of life after G-POEM measured with SF-36 questionnaire
Table 5
6

Table 6 Univariable analysis of predictors of G-POEM clinical success
at 12 months

Gastric retention >20% at 4 hours
before G-POEM
Early response to G-POEM
Clinical success at 1 month
Medication use after the G-POEM

*Compared with idiopathic aetiology.
†2.6 cut-off point was identified using receiver operating characteristic curve and
Youden’s Index (details not presented).
BMI, body mass index; GCSI, Gastroparesis Cardinal Symptom Index; GES, gastric
emptying study; G-POEM, gastric per-oral endoscopic myotomy.

In this study, the repeated evaluation of the GCSI Score
allowed the assessment of mid-term durability of G-POEM. The
participants were recruited from five tertiary referral centres
and included all subtypes of gastroparesis and a wide range of
age and BMI. The diversity of the participants increases external
validity and thus generalisability of the results of this study.

Figure 3 Comparison of clinical success rate between the groups with
clinical success and clinical failure at 1 month over study follow-up time
points. Numbers are presented for the 73 patients (91%) with available
1-month clinical follow-up.
Vosoughi K, et al. Gut 2021;0:1–9. doi:10.1136/gutjnl-2020-322756

Gut: first published as 10.1136/gutjnl-2020-322756 on 19 March 2021. Downloaded from http://gut.bmj.com/ on April 22, 2021 at Henry Ford Hospital. Protected by copyright.

Change between baseline
and 12 months

Endoscopy

Endoscopy

95% CI

P value

Baseline GCSI Score higher than 2.6 3.23

OR

(1.06 to 9.9)

0.04

Gastric retention >20% at 4 hours
before G-POEM

(1.14 to 11.66)

0.029

3.65

Note: the following variables were tested in the model: upper abdominal pain
before G-POEM, baseline GCSI Score higher than 2.6, baseline nausea/vomiting,
baseline Fullness/early satiety, baseline bloating score and gastric retention >20%
at 4 hours before G-POEM.
GCSI, Gastroparesis Cardinal Symptom Index; G-POEM, gastric per-oral endoscopic
myotomy.

Clinical success was achieved in 56% of the patients at 12
months, which is lower than the 73%–90% success rate reported
by previous studies.20 21 34 Most of the previously published
studies, however, were retrospective in nature, with a small
sample size, and some without a clearly defined eligibility
criteria. Moreover, the discrepancy in success rate can partially be
explained by lack of a standardised definition of clinical success.
In a number of the previous studies, clinical success was defined
as improvement of GCSI Score after G-POEM procedure.
In this study, we initially defined the clinical success primary
endpoint as mean GCSI Score below 2. As primary retrospective reports on G-
POEM became available in the literature,
we modified the clinical success definition to a decrease of one
average GCSI Score with >25% decrease in at least two GCSI
subscales. The revised definition was first introduced by Mekaroonkamol et al24 and was subsequently used by more studies
on G-POEM.35 36 Previous studies which reported minimal
important difference (MID) of GCSI Score confirm that the
definition of clinical success used in our study represents a clinically meaningful improvement of gastroparesis symptoms. MID
represents the smallest improvement perceived by patients as
beneficial. A randomised clinical trial, which used GCSI Score
to test a novel ghrelin receptor agonist for diabetic gastroparesis,
estimated that MID for total GCSI Score was 0.94.37 Moreover,
Revicki et al38 estimated that the MID for a composite score of
4 items of the GCSI-Daily Diary (GCSI-DD) (nausea, bloating,
excessive fullness and postprandial fullness), as a simpler validated alternative to the original GCSI-
DD, was 0.73. These
results suggest that the revised primary endpoint of this study,
which includes one score decrease in the mean GCSI total score,
represents a clinically significant improvement of gastroparesis
symptoms.
In our sample population, clinical success rates based on the
revised definition (decrease of one average GCSI Score plus 25%
decrease in 2 GCSI subscales) were generally comparable to the
rates of the patients with GCSI below 2 (the initial primary
endpoint of the study) across the follow-up time points. Particularly, the clinical success rate at 12 months was moderately lower
than the rate of the patients with GCSI below 2 at 12 months.
This study demonstrated that clinical improvement after
the G-POEM procedure was sustained over the course of the
study. This finding is in agreement with a retrospective study
that included 30 cases and showed the clinical improvement
after G-POEM was sustained 18 months after the procedure.39
Our results showed that early response to G-POEM predicts the
clinical success at 12 months after the G-POEM. These findings provide valuable information about the pattern of response
to G-POEM over time and helps gastroenterologists with early
decision-
making regarding the next management plan after
performing G-POEM.
Vosoughi K, et al. Gut 2021;0:1–9. doi:10.1136/gutjnl-2020-322756

Our multivariate model showed that the severity of clinical
symptoms at baseline and pre G-POEM gastric retention >20%
at 4 hours were independent predictors of clinical success. This
finding suggests that G-POEM should be considered in patients
with more severe symptoms along with significant retention on
GES. Aetiology and duration of gastroparesis have been suggested
by retrospective studies to be potential baseline predictors of
clinical success. One study on refractory gastroparesis suggested
that longer duration of gastroparesis predicted a worse outcome
with G-POEM.40 Other studies have suggested that patients with
non-diabetic gastroparesis were more likely to have a favourable
outcome after G-POEM.41 42 However, conflicting data have
demonstrated that diabetes predicts the improvement of pylorus
characteristics following G-POEM.43 Our findings did not show
a significant association between clinical success and duration or
aetiology of gastroparesis. In addition to clinical criteria, study of
antral motility and pyloric spasm has been proposed to provide
valuable data for optimal patient selection before G-POEM.44
Our results have important clinical and health service implications. Gastroparesis remains a clinically challenging syndrome
with limited therapeutic options.45 The prevalence of gastroparesis, emergency department visits and number of hospitalisations
in the USA and the associated charges have increased during the
past decade.46 47 Our results show that G-POEM is a modestly
effective, minimally invasive procedure that provides patients
with a durable outcome in terms of symptom improvement and
quality of life, suggesting that G-POEM may lead to reduction in
healthcare cost and burden of refractory gastroparesis.
In this study, we used FCS MI method to impute the missing
data regarding G-POEM efficacy. Simulation studies have shown
that FCS MI generally provides unbiased estimates with appropriate coverage.32 33 However, the main assumption is that data
are missing at random.31 Our results showed that the baseline
clinical characteristics and clinical success rate at 1 month were
comparable between the patients with complete and those with
missing 12-
month follow-
up. Moreover, the rate of missing
12-
month follow-
up was only 6%. Although proportion of
missing data is not the only factor that determines the influence
of missing data, it has been suggested that statistical analysis is
unlikely to be biased with less than 10% missingness.48
Our study has several limitations. First, this study lacks a
placebo control group; hence, the estimation of the absolute
clinical success rate and sham/placebo effect of G-POEM was
not possible. Although G-POEM has not been compared with
a placebo-
controlled group, previous studies suggested the
occurrence of a major placebo effect after other treatment
options of gastroparesis, including pylorus-targeted interventions.49–51 This study limitation should be addressed in sham-
controlled randomised trials on G-POEM. Second, inability to
sufficiently control important confounding variables could be
a major threat to the study’s internal validity. For example, the
effect of prokinetic use might be a potential confounder which
was not considered in the definition of the primary endpoint.
Moreover, the outcome of the prior gastroparesis interventions was not recorded, whereas studies have suggested that
response to prior pylorus directed intervention might predict
the outcome of G-POEM.52 Third, several patients were not
available for repeat gastric emptying study at 3 months after the
procedure; thus, no conclusion can be drawn about improvement or normalisation of gastric emptying of those patients.
Lastly, gastric emptying was not evaluated at 12 months after
the study, concurrently with the study’s primary endpoint.
Gastric emptying results at 12 months would provide more
information to investigate the mid-term objective response to
7
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Table 7 Predictors of G-POEM clinical success at 12 months tested
by multivariable logistic regression model
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treatment as well as the correlation between the objective and
subjective outcomes.
In conclusion, G-POEM is safe and most AEs are mild. It is
modestly effective for management of refractory gastroparesis
after a follow-up period of 12 months. Severity of baseline clinical
symptoms and significant (>20%) retention on preprocedural
GES predicted the clinical success at 12 months. We suggest that
G-POEM should continue to be performed as part of prospective IRB-approved studies to aid. These studies will be crucial to
help further identify optimal candidates for G-POEM. Concurrently, we should strive to study different available methods to
identify patients with pylorospasm. These include endoluminal
functional luminal imaging probe (EndoFLIP; Crospon, Galway,
Ireland), antroduodenal manometry, dynamic gastric MRI and
scintigraphy.
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